🇨🇦Canadian I Respirologist🫁| PH-ILD Doctor @uhn| Alumnus @UNB @WesternU @mcmasterU @uniofeastanglia. Founder of coreSR.ai.
Toronto
- Tweets 1,209
- Following 788
- Followers 581
- Likes 2,094
Pinned Tweet
Our CARE-PF analysis is out in Respirology.
n=4236 fibrotic ILD. Transplant-free survival 91%/72%/57% at 1/3/5 yr (IPF 39%; CTD-ILD 70% at 5 yr).
@UofT @UHN @UofT_DoM
doi.org/10.1002/resp.70305
2
2
275
Adult idiopathic ILD can be surfactant-gene disease—often missed.
SR n=162 (SFTPA/C, ABCA3, NKX2-1): onset 19–79y; SFTPA familial ± lung Ca; NKX2-1 thyroid/neuro; CT indeterminate.
Genetics: family Hx, younger fibrosis, multi-organ clues.
doi.org/10.1080/25310429.202…
#ILD #IPF
1
1
113
Why SLE breeds PAH: BAFF drives a B→T→endothelium axis (Circ Res).
BAFF-Tg mice get SLE+PAH; B cells activate Gzmk+ CD8s → FasL endothelial apoptosis. Belimumab helped in 2 models.
Promising SLE-PAH target—animal data, not a pt RCT
doi.org/10.1161/CIRCRESAHA.1…
#PAH #PH #MedTwitter
56
PA dilation tempts as a PH screen in lung disease—fibrosis blunts it.
PVDOMICS n=252: PA size tracked mPAP (ρ≈0.5) & PH (OR~4–6). AUC~0.79; weaker in ILD (0.70) vs obstructive (0.87).
Don't call PH from PA size alone in fibrotic ILD.
doi.org/10.1016/j.chest.2026…
#ILD #PH #PulmTwitter
1
1
189
Inhaled treprostinil now has pooled phase 3 FVC numbers in IPF—not just PH-ILD.
TETON-1+2, n=1191. 52-wk FVC -45 vs -162 ml (diff +112, p<0.0001); delayed worsening too.
Clear FVC signal on antifibrotics. Caveat: cough; deaths NS.
doi.org/10.1093/ajrccm/aamag…
#IPF #ILD #PulmTwitter
1
3
332
Myositis-ILD AE: inpatient mortality still high — MDA5 + low CD4+ mark the worst.
n=35 DM/PM-AEILD: death 42.9% (66.7% anti-MDA5+). CD4+ best predictor (AUC 0.933; cut-off 373/µL).
Stratify early. Small retrospective cohort.
doi.org/10.1007/s10067-026-0…
#ILD #MedTwitter #PulmTwitter
69
Our TITAN-SR validation paper is out in Journal of Clinical Epidemiology.
Biomedical BERT ensemble for title/abstract screening — trained on ~20k reviews — beat ASReview and commercial LLM chatbots.
doi.org/10.1016/j.jclinepi.2…
#SystematicReview #EvidenceSynthesis
1
1
1
48
Our TITAN-SR paper is out in J Clin Epidemiol.
A biomedical BERT ensemble for systematic-review title/abstract screening — developed and externally validated against active learning and LLM chatbots.
doi.org/10.1016/j.jclinepi.2…
#SysRev #MedTwitter #EvidenceSynthesis
1
4
293
Headline from the paper: the BERT ensemble outperformed active learning and LLM chatbots for title/abstract screening on external validation.
Screening is classification, not conversation. Build the specialist.
coresr.ai
#SystematicReview #AI
1
13
TITAN-SR powers screening inside CoreSR — search → RoB → extraction → NMA/GRADE → draft.
Paper: doi.org/10.1016/j.jclinepi.2…
Platform: coresr.ai
Thanks to Zeraatkar, Granton, Busse, Rochwerg, Guyatt.
#CoreSR #JClinEpi
8
PAH risk scores miss the RV. ULTRA RIGHT VALUE puts echo back in.
n=401 prevalent PAH. RV echo (esp. RV–PA coupling) ↑ ESC/ERS c-index 0.73→0.78; REVEAL 0.74→0.79.
Caveat: prevalent cohort; needs external validation.
doi.org/10.1093/ehjci/jeag23…
#PAH #PH #MedTwitter #PulmTwitter
91
Inoperable CTEPH: BPA+riociguat vs riociguat alone?
PRACTICE RCT: 12-mo PVR −5.0 vs −2.6 WU (adj Δ −3.0; p=0.007); mPAP Δ −7.8 mmHg for combo.
Bigger hemodynamic win—but bleeding 30% vs 3%.
Caveat: center expertise matters.
doi.org/10.1186/s12931-026-0…
#CTEPH #PH #PulmTwitter
247
Tyler Pitre, MD PhD🇨🇦 retweeted
UHN was just named by @newsweek as the no. 1 hospital in Canada for:
🥇 Cardiology
🥇 Cardiac Surgery
🥇 Endocrinology
🥇 Gastroenterology
🥇 Nephrology
🥇 Pulmonology
🥇 Oncology
🥇 Neurosurgery
Learn more about the 2027 World's Best Specialized Hospitals:
rankings.newsweek.com/worlds…
4
28
97
6,174
CoreSR now offers a free tier, forever, for the full manual systematic review workflow.
No AI, no review limit, no expiration date. Screening, data extraction, risk-of-bias assessment, and meta-analysis run on the platform at no cost, for as many reviews as your team needs.
Most platforms gate the basics behind a trial that expires or a seat that costs money from day one. We built CoreSR around AI-assisted screening and GRADE certainty automation on network meta-analysis, and those stay paid features. But a reviewer, a student, or a society shouldn't need a credit card to run a modern systematic review. The manual tools stay free, permanently.
See the platform in action: lnkd.in/gSYP4KFg
Try it at coresr.ai.
hashtag#systematic review, #coresr.ai
1
1
45
CoreSR now offers a free tier, forever, for the full manual systematic review workflow.
No AI, no expiration date. Includes a platform for screening, rob 2.0, pairwise meta-analysis and data extraction.
lnkd.in/gSYP4KFg Try it at coresr.ai
#SR #AI
77
ATMOS now in Thorax: inhaled mosliciguat Phase 1b, dose escalation in PAH/CTEPH (n=38). In NO-nonresponsive PPS (n=20), peak PVR −38% at 2 mg / −36% at 4 mg; CO ↑~25% at top dose; mild AEs, no BP signal. Single-dose PoC—not chronic efficacy. doi.org/10.1136/thorax-2025-…
1
2
231
IPF-PRO case-crossover: same-day PM2.5 and respiratory hospitalization in IPF. +5 µg/m³ on lag 0 → OR +22% (95% CI 14–47%). No other lag-day signal; no mod by MUC5B, telomere length, or antifibrotics.
doi.org/10.1093/annalsats/aa…
85
PADN-HF-PH (NEJM): n=264 PH-LHD, China RCT. PADN+GDMT vs GDMT. 2-yr KM clinical worsening 25.7% vs 51.5% (HR 0.49, 0.30–0.82; med FU 338d). Open-label, single-country — needs sham-controlled replication before it moves Group 2 practice.
doi.org/10.1056/NEJMoa260905…
1
220